MedPlus discloses fresh regulatory action

MedPlus Health Services Limited has reported another drug license suspension at a subsidiary pharmacy operated by Optival Health Solutions Private Limited in Karnataka. The latest regulatory action could result in a potential revenue impact of ₹2.88 lakh and adds to similar suspensions previously reported in Telangana and Andhra Pradesh.

MedPlus Health Services Limited has informed stock exchanges about an additional drug license suspension affecting one of the retail outlets operated by its subsidiary, Optival Health Solutions Private Limited.

The latest suspension was issued by the Drugs Control Administration in Karnataka for a pharmacy located near the Bidadi Bus Stand in Ramanagar district. The suspension order, received on March 14, 2026, temporarily halts the store’s drug license for two days.

According to the company’s regulatory filing, the action may lead to an estimated revenue impact of approximately ₹2.88 lakh during the suspension period.

Multiple Enforcement Actions Across States

The new suspension adds to a series of regulatory actions faced by the subsidiary’s pharmacy outlets across multiple states including Karnataka, Telangana and Andhra Pradesh.

These enforcement measures were issued under Rule 65 of the Drugs and Cosmetics Rules, 1945, framed under the Drugs and Cosmetics Act, 1940, which governs the sale and distribution of pharmaceutical products in India.

Authorities from state drug control administrations carried out the inspections and issued suspension orders for specific outlets.

Stores Affected by Suspension Orders

Location Authority Suspension Period Potential Revenue Loss

Kempegowda Circle, Ramanagar (Karnataka) Assistant Director, Drugs Control Administration, Bangalore South Circle 2 days ₹1.07 lakh

Dilsukhnagar Alkapuri (Telangana) Assistant Director, Drugs Control Administration, Rangareddy 3 days ₹1.60 lakh

Penuganchiprolu Main Road (Andhra Pradesh) Assistant Director, Drugs Control Administration, NTR & Krishna Districts 7 days ₹2.12 lakh

Bidadi Bus Stand, Ramanagar (Karnataka) Assistant Director, Drugs Control Administration, Bangalore South Circle 2 days ₹2.88 lakh

Among the affected locations, the Bidadi store carries the highest potential revenue loss despite having a relatively short suspension period.

Disclosure Under SEBI Regulations

The company disclosed the regulatory developments in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The filing was signed by the company’s compliance officer and company secretary, confirming that the information had been submitted to stock exchanges following the receipt of the latest order.

The disclosure also referenced relevant regulatory circulars issued by the Securities and Exchange Board of India to ensure transparency regarding material events affecting listed companies.

Transparency and Public Disclosure

MedPlus Health Services Limited stated that complete details related to the regulatory actions will be made available on its official website and through filings with stock exchanges including the BSE Limited and the National Stock Exchange of India.

The company said the disclosure was made to maintain transparency with investors and stakeholders while complying with regulatory reporting requirements.

Retail Pharmacy Operations Under Scrutiny

The recent suspensions highlight increasing scrutiny of pharmacy operations by state drug control authorities, particularly regarding compliance with drug sale regulations under the Drugs and Cosmetics framework.

Retail pharmacy chains operating across multiple states often face periodic inspections by regulators to ensure adherence to licensing conditions, storage standards and prescription compliance.

While the suspensions in this case are temporary, repeated regulatory actions can potentially affect store operations and revenue generation if compliance gaps persist.

For now, MedPlus has quantified the potential revenue impact from the affected outlets and confirmed that the information has been disclosed in accordance with regulatory norms.